Enzalutamide Effective, Well Tolerated in Elderly Patients With Prostate Cancer

Share this content:
Enzalutamide was associated with improved overall survival in elderly men with castration-resistant prostate cancer (mCRPC).
Enzalutamide was associated with improved overall survival in elderly men with castration-resistant prostate cancer (mCRPC).

Enzalutamide was associated with improved overall survival and radiographic progression-free survival compared with placebo in elderly men 75 years or older with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) and was well tolerated, a study published in the journal Annals of Oncology has shown.1

Because prostate cancer disproportionately affects older men and age impacts patient management, it is important to understand the efficacy and safety of advanced prostate cancer therapies in elderly men.

Therefore, researchers performed an analysis of the phase 3 PREVAIL trial to assess the safety and efficacy of enzalutamide, an androgen receptor inhibitor, in patients aged 75 years or older.

In the double-blind, international, PREVAIL trial, 1717 chemotherapy-naïve men with mCRPC were randomly assigned to receive enzalutamide 160 mg orally daily or placebo. Of those, 609 patients were elderly.

RELATED: Dose-intensified SRT Minimally Impacts Quality of Life in Biochemical Recurrent Prostate Cancer

Results showed that overall survival was 32.4 months (95% CI: 27.7-not yet reached) in the enzalutamide group and 25.1 months (95% CI: 22.6-28.0) in the placebo group among elderly patients (HR, 0.61; 95% CI: 0.47-0.79; P = .0001). Radiographic progression-free survival was not yet reached (95% CI: 12.3-not yet reached) vs 3.7 months (95% CI: 3.6-5.3), respectively (HR, 0.17; 95% CI: 0.12-0.24; P < .0001).

In regard to safety, the incidence of adverse events was similar in both treatment arms, but there was an overall higher incidence of falls among elderly patients compared with younger patients and among elderly patients receiving enzalutamide vs those receiving placebo.

Reference

  1. Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL [published online ahead of print November 16, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv542.

Enzalutamide was associated with improved overall survival and radiographic progression-free survival compared with placebo in elderly men 75 years or older with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) and was well tolerated, a study published in the journal Annals of Oncology has shown.1

 

Because prostate cancer disproportionately affects older men and age impacts patient management, it is important to understand the efficacy and safety of advanced prostate cancer therapies in elderly men. Therefore, researchers performed an analysis of the phase 3 PREVAIL trial to assess the safety and efficacy of enzalutamide, an androgen receptor inhibitor, in patients aged 75 years or older.

 

In the double-blind, international, PREVAIL trial, 1717 chemotherapy-naïve men with mCRPC were randomly assigned to receive enzalutamide 160 mg orally daily or placebo. Of those, 609 patients were elderly.

 

Results showed that overall survival was 32.4 months (95% CI: 27.7-not yet reached) in the enzalutamide group and 25.1 months (95% CI: 22.6-28.0) in the placebo group among elderly patients (HR, 0.61; 95% CI: 0.47-0.79; P = .0001). Radiographic progression-free survival was not yet reached (95% CI: 12.3-not yet reached) vs 3.7 months (95% CI: 3.6-5.3), respectively (HR, 0.17; 95% CI: 0.12-0.24; P < .0001).

 

In regard to safety, the incidence of adverse events was similar in both treatment arms, but there was an overall higher incidence of falls among elderly patients compared with younger patients and among elderly patients receiving enzalutamide vs those receiving placebo.

 

Reference

Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL [published online ahead of print November 16, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv542

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters